https://pharmadevicenews.com/what-does-gondolabios-childrens-tumor-foundation-partnership-mean-for-nf1-drug-research/ PharmaDeviceNews en 2026-10-24T04:40:54+00:00 What does GondolaBio’s Children’s Tumor Foundation partnership mean for NF1 drug research? Annette Bakker, BridgeBio Pharma, Charlie Ge, Children's Tumor Foundation, Cybele Gouverneur, GondolaBio, neurofibromatosis type 1, NF1, selumetinib https://pharmadevicenews.com/wp-content/uploads/2026/04/Whitehawk-Therapeutics-expands-its-oncology-narrative-with-AACR-2026-data-across-three-ADC-candidates-e1776662901880.webp https://pharmadevicenews.com/summit-therapeutics-partners-with-lunit-to-study-ai-tumor-biomarkers-for-ivonescimab/ PharmaDeviceNews en 2026-10-24T04:36:10+00:00 Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab Akeso, HARMONi, HARMONi-3, HARMONi-7, Ivonescimab, Lunit, Lunit SCOPE IO, SMT112, Summit Therapeutics, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/05/Antengenes-CLINCH-3-clearance-puts-ATG-022-into-the-pivotal-gastric-cancer-race-e1779981022130.webp https://pharmadevicenews.com/travere-therapeutics-filspari-shows-sustained-biomarker-reductions-in-phase-3-protect-study/ PharmaDeviceNews en 2026-10-24T04:31:56+00:00 Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study American Society of Nephrology, FILSPARI, PROTECT, sparsentan, Travere Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/06/Mercks-Keytruda-and-Welireg-approval-reshapes-adjuvant-kidney-cancer-competition-e1781439990456.webp https://pharmadevicenews.com/genialis-ai-predicts-cancer-treatment-response-in-small-clinical-trials-using-biology-first-models/ PharmaDeviceNews en 2026-10-24T04:02:35+00:00 Genialis AI predicts cancer treatment response in small clinical trials using biology-first models European Society for Medical Oncology, Genialis, Genialis Supermodel, GitLab, KRAS G12C, pembrolizumab, Sid Sijbrandij, sotorasib https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Clinical-Trials.webp https://pharmadevicenews.com/advancell-reports-80-psa-response-with-advc001-in-updated-phase-1-prostate-cancer-study/ PharmaDeviceNews en 2026-10-24T03:57:34+00:00 AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study AdvanCell, ADVC001, European Society for Medical Oncology, Lead-212, Novartis, Pluvicto, Princess Alexandra Hospital, prostate-specific membrane antigen, South Australian immunoGENomics Cancer Institute, TheraPb https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/galderma-wins-china-approval-for-relfydess-but-can-its-six-month-wrinkle-treatment-challenge-established-botox-rivals/ PharmaDeviceNews en 2026-10-23T06:56:09+00:00 Galderma wins China approval for Relfydess, but can its six-month wrinkle treatment challenge established Botox rivals? Alluzience, China, Dysport, Galderma Group AG, National Medical Products Administration, PEARL Technology, READY-1, relabotulinumtoxinA, Relfydess https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/eqt-offers-qiagen-shareholders-a-40-premium-but-can-its-e10-8bn-diagnostics-bet-unlock-faster-growth/ PharmaDeviceNews en 2026-10-23T06:32:10+00:00 EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth? Abu Dhabi Investment Authority, CPP Investments, Crown NL Bidco, EQT AB, EQT XI, QIAcuity, QIAGEN N.V., QIAstat-Dx, QuantiFERON, Thermo Fisher Scientific https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Diagnostics-generic-1.webp https://pharmadevicenews.com/merck-and-moderna-report-42-lower-melanoma-recurrence-risk-in-phase-3-mrna-trial/ PharmaDeviceNews en 2026-10-23T06:24:49+00:00 Merck and Moderna report 42% lower melanoma recurrence risk in Phase 3 mRNA trial European Society for Medical Oncology, Georgina Long, INTerpath-001, intismeran autogene, KEYNOTE-942, Keytruda, Merck & Co., Moderna, pembrolizumab, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/drug-farm-reports-df-003-reduces-kidney-fibrosis-in-preclinical-alpk1-study/ PharmaDeviceNews en 2026-10-23T06:20:22+00:00 Drug Farm reports DF-003 reduces kidney fibrosis in preclinical ALPK1 study ALPK1, American Society of Nephrology, ASN Kidney Week, DF-003, Drug Farm, INSERM, Institut Pasteur, ROSAH syndrome, Université Paris Cité https://pharmadevicenews.com/wp-content/uploads/2026/07/Arcus-Biosciences-Q2-call-could-clarify-its-post-domvanalimab-development-strategy-e1784703447940.webp https://pharmadevicenews.com/gilead-sciences-makes-a-1-275bn-bet-on-an-early-stage-oral-drug-can-hcxt-2001-challenge-injectable-ibd-therapies/ PharmaDeviceNews en 2026-10-23T06:10:07+00:00 Gilead Sciences makes a $1.275bn bet on an early-stage oral drug. Can HCXT-2001 challenge injectable IBD therapies? Emvistegrast, Gilead Sciences, GS-1427, HCXT-2001, icotrokinra, Johnson & Johnson, PepStar Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/06/cAMPfield-targets-ulcerative-colitis-and-Crohns-disease-with-a-selective-PDE4B-strategy-e1781934419210.webp